Rociletinib (CO-1686) USA Expanded Access Program

NO_LONGER_AVAILABLE

Conditions studied: Non-small Cell Lung Cancer

In brief

To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+).

Key facts

Study ID

NCT02547675

Run by

Clovis Oncology, Inc.

Last updated by the study team

2018-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Arizona — Scottsdale, Arizona, United States
• Compassionate Care Research Group, Inc. — Fountain Valley, California, United States
• Pacific Cancer Care — Monterey, California, United States
• Sutter Cancer Institute — Sacramento, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• Halifax Health - Center for Oncology — Daytona Beach, Florida, United States
• UF Health Center Orlando — Orlando, Florida, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Billings Clinic — Billings, Montana, United States
• Tulsa Cancer Institute — Tulsa, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.